论文部分内容阅读
寻找具有明显促进造血系统全血象恢复功能,同时显示最小毒副作用的抗辐射药物,已成为国防和临床医学上用来应对急性放射性病与肿瘤放化疗所导致的骨髓造血功能损伤的热点。裴秀芝等通过对最新相关文献的检索和综述,分析比较了几种被广泛报道和应用的造血因子在作用机制、动物及人体试验的功效、给药时间、给药剂量和毒副作用等方面的特点。发现,重组白介素12(IL-12)是目前发现唯一能够促进骨髓造血系统全血象长久恢复的细胞因子,是唯一能在辐射后24 h给药也显示全血象恢复功能的蛋白。IL-12的有效剂量非常低,只需一次注射,对动物和病人带来最小的毒副作用。作为抗辐射药以及肿瘤放化疗的辅助治疗药物,重组人IL-12具有巨大的药物开发价值和临床应用价值。
The search for anti-radiation drugs that have the obvious function of promoting the whole blood image restoration of the hematopoietic system and showing the minimum toxicities and side effects has become a hot spot in the defense and clinical medicine to deal with the bone marrow hematopoietic dysfunction caused by acute radiation sickness and tumor radiotherapy and chemotherapy. By searching and reviewing the latest relevant literature, Pei Xiuzhi et al. Analyzed and compared the widely used and widely used hematopoietic factors in the mechanism of action, efficacy of animal and human trials, administration time, dose and side effects . It is found that recombinant interleukin-12 (IL-12) is the only cytokine that has been found to promote long-term recovery of whole blood in bone marrow hematopoietic system and is the only protein capable of restoring whole blood after 24 h of irradiation. The effective dose of IL-12 is very low, only one injection, the animals and patients with minimal toxicity. As an anti-radiation medicine and adjuvant therapy for tumor radiotherapy and chemotherapy, recombinant human IL-12 has great value in drug development and clinical application.